International Symposium on αβ T-Cell/CD19 B-Cell Depleted Haploidentical HSCT

8:00-8:10am 

Opening Remarks: Alice Bertaina, MD, PhD, Associate Professor; Section Chief, Pediatric Hematology, Oncology, Stem Cell Transplantation & Regenerative Medicine and Medical Director of Inpatient Services; Co-Director Bass Center for Childhood Cancer and Blood Diseases, Stanford University

8:10-8:20am

Welcome:   Lloyd Minor, Dean, School of Medicine, Stanford University and Paul A. King, President and CEO, Lucile Packard Children's Hospital

Opening Keynote

8:20-9:10am

Introduction of Keynote: Robertson Parkman, MD, Adjunct Professor of Pediatrics,Pediatric Hematology, Oncology, Stem Cell Transplantation & Regenerative Medicine, Stanford University

Keynote: Yair Reizner, MD, PhD, Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center

Title: The History of T-cell Depleted Haploidentical HSCT

Session 1: Adaptive versus Innate Immunity in ab T-cell/CD19 B-cell Depleted Haploidentical HSCT: which one matters?                                                                                                                                             

Moderator: Leslie S. Kean, MD, PhD, Director, Stem Cell Transplant Center, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School

9:10-9:40am

Jürgen Kuball, PhD, Professor, UMC Utrecht Cancer Center, UMC Utrecht, Netherlands

Title: The Biology of gd T cells: Is this the secret for the success?

9:40-10:10am 

Alice Bertaina, MD, PhD, Associate Professor, Stanford University

Title: ab T-cell/CD19 B-cell Depleted Haploidentical HSCT: A Platform for Immunotherapy

10:10-10:20am

Q&A and Session Discussion

10:20-11:00am

BREAK

11:00-11:30am

Susan E. Prockop, MD, Head, Clinical Research Stem Cell Transplantation and Cellular Therapies Service, Memorial Sloan Kettering Cancer Center 

Title: Immune Reconstitution After T-cell Depleted Haploidentical HSCT

11:30-12:00pm 

Andrew Gennery, MD, Professor in Pediatric Immunology and HSCT,

Institute of Translational and Clinical Research, Pediatric Immunology Dept., Great North Children's Hospital, Newcastle University, UK

Title: ab T-cell/CD19 B-cell Depleted Haploidentical HSCT in PIDs: The UK Experience

12:00-12:30pm

Michael Maschan, Department Lead, Department of Hematopoietic Stem Cell Transplantation, Dmitriy Rogachev National Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia

Title: Viral Infections After ab T-cell/CD19 B-cell Depleted Haploidentical HSCT: The Role of CD45RA+ Depleted DLI

12:30-12:45pm

Q&A and Session Discussion

12:45-1:30pm

BREAK

1:30-2:00pm

Wolfgang Bethge, MD, Associate Professor, Hematology and Oncology Hematopoietic Stem Cell Transplantation, University of Tübingen, Germany

Title: ab T-cell/CD19 B-cell Depleted Haploidentical HSCT in Adults

2:00-2:30pm 

Robert Lowsky, MD, Professor of Medicine, Blood and Marrow Transplantation and Cellular Therapy, Stanford University 

Title: New Approaches to Boost GvL after T-cell Depleted Haploidentical HSCT: The Experience of the Stanford Adult BMT Group

2:30-2:45 pm   

2:45-3:00pm 

Q&A and Session Discussion

Conclusions of the day – Alice Bertaina, MD, PhD, Stanford University

Day 2: 

7:20-7:30am

Welcome Introduction: Maria Grazia Roncarolo, MD, George D. Smith Professor in Stem Cell and Regenerative Medicine; Professor of Pediatrics and Medicine, Director of the Center for Definitive and Curative Medicine, and Co-Director of the Institute for Stem Cell Biology and Regenerative Medicine, Stanford University

Session 4: Is ab T-cell/CD19 B-cell Depletion the Best Platform for haploidentical HSCT? Let’s debate

Moderator: Michael Pulsipher, MD, Section Head, Transplantation and Cellular Therapy, BMT Clinical Research, Hematology, Oncology and Blood and Marrow Transplantation; Professor of Clinical Pediatrics, Keck School of Medicine of University of Southern California

7:30-8:00am

Franco Locatelli, MD, Full Professor of Pediatrics, Sapienza University of Rome; Director,  Department of Pediatric Hematology and Oncology, IRCCS Ospedale Bambino, Rome, Italy Title: ab T-cell/CD19 B-cell Depleted Haploidentical HSCT  

8:00-8:30am

Brandon Triplett, MD, Associate Member, St. Jude Faculty; Chief, Bone Marrow Transplant Clinical Service, Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital

Title: CD45RA+ Depleted Haploidentical HSCT 

8:30-9:00am

Kenneth Cooke, MD, Herman and Walter Samuelson Professor, Director, Pediatric Bone Marrow Transplantation Program, Johns Hopkins Kimmel Cancer Center 

Title: Haploidentical HSCT with PT-Cy

9:00-9:15am

Q&A and Session Discussion

9:15-10:00am

10:00-10:20am

Agnieszka Czechowitz, MD, PhD, Assistant Professor, Pediatric Hematology, Oncology, Stem Cell Transplantation & Regenerative Medicine, Stanford University

Title: ab T-cell/CD19 B-cell Depleted Haploidentical HSCT Combined with Antibody Conditioning Regimen for Fanconi Anemia

10:20-10:40am

Joseph Oved, MD, MA, Attending Physician, Division of Hematology, Children's Hospital of Philadelphia

Title: ab T-cell/CD19 B-cell Depleted Mismatched HSCT for Severe Aplastic Anemia

10:40-11:00am

Alice Bertaina, MD, PhD, Associate Professor, Stanford University

Title: ab T-cell/CD19 B-cell Depleted Haploidentical HSCT and Solid Organ Transplant to Promote Functional Immune Tolerance

11:00-11:20am

Christopher Dvorak, MD, Chief, Division of Pediatric Allergy, Immunology and Bone Marrow Transplantation; Medical Director, Pediatric Cellular Therapy Laboratory, UCSF Benioff Children's Hospital, UCSF

Title: Non TBI-based Conditioning for Acute Lymphoblastic Leukemia NGS MRD Negative

11:20-11:40am

Matthew Porteus, MD, PhD, Sutardja Chuk Professor of Definitive and Curative Medicine; Professor of Pediatrics, Pediatric Hematology, Oncology, Stem Cell Transplantation & Regenerative Medicine; Co-Director, Center for Definitive and Curative Medicine, Stanford University 

Title: ab T-cell/CD19 B-cell Depleted Haploidentical HSCT and CAR T Cells

11:45-12:00pm

Q&A and Session Discussion

Closing Keynote:

12:00-12:50pm

Introduction of Closing Lecture: Tanja Gruber, MD, PhD, Endowed Professor for Pediatric Cancer; Division Chief, Pediatric Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Stanford University; Director, Bass Center for Childhood Cancer and Blood Diseases, Stanford University

 Closing Lecture: Rupert Handgretinger, MD, PhD, Professor of Pediatrics; Chairman, Department of General Pediatrics and Hematology/Oncology, Children’s University Hospital, Tübingen, Germany

Title: The Future of T-cell Depleted HSCT

12:50-1:00pm

Closing Remarks: Alice Bertaina, MD, PhD, Stanford University